Sök - Finansinspektionen

Börsdata Terminal

The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. Köp aktien Cyxone AB (CYXO). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod Jan 15 2021 Key statistics On Thursday, Cyxone AB (CYXO:STO) closed at 5.00, 67.50% above the 52 week low of 2.99 set on Apr 03, 2020. 2020-12-09 08:26:36 Cyxone has decided to apply for a listing of its share on Nasdaq Stockholm Main Market +1,03% | 1,48 MSEK 2020-12-08 14:46:49 Cyxone receives regulatory approval to initiate a clinical Phase 2 study with Rabeximod in Covid-19 patients +0,35% | 1,94 MSEK Cyxone (publ.) meddelar idag att Nasdaq Mid Cap Teckningsperiod 18 mar - 25 mar Första handelsdag 26 mar.

BioStock Studio: SenzaGen is aiming to increase market activity in 2021. 4 mars, 2021. 2021-03-19 · Handeln i forskningsbolaget Cyxone stoppades på måndagseftermiddagen, efter en uppgång på 19 procent på First North-listan. Det framgår av ett börsmeddelande. TradingView UK. View live CYXONE AB chart to track its stock's price action. Find market predictions, CYXO financials and market news.

Cyxone undersöker möjligheten att byta lista till Nasdaq Main

companies: 4,776 total market cap: $88.657 T. Global Cyxone (publ.) meddelar idag att styrelsen har beslutat att ansöka om en notering av bolagets aktie på Nasdaq Stockholms huvudlista. Bolaget avser att lämna in en noteringsansökan under första kvartalet 2022. Cyxone är för närvarande noterat på Nasdaq First North Growth Market. Cyxone ligger i en fallande trendkanal på medellång sikt.

Cyxone - mot miljardvärdering Redeye

The product candidates of the company include T20K and Rabeximod. Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who really controls Cyxone AB (publ) (STO:CYXO Cyxone investigates listing on Nasdaq Main Market Nordic Small Cap A listing on Nasdaq Nordic Small Cap would provide conditions for improved liquidity in the share, increase the attention from international analysts, and for institutional investors to consider investing in Cyxone.

Portfolios. Company information for Cyxone AB NPV share priceincluding general stock details, shortly before the market opens, Market cap: 275.34 million SEK Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. Cyxone AB: SE0007815428: 2021-03-01: 40000: Antal: 4,37: SEK: FIRST NORTH SWEDEN: Historik: Detaljer: 2021-03-04: Cyxone AB: Bert Roland Kari Junno: Styrelseordförande: Förvärv: Cyxone AB: SE0007815428: 2021-03-02: 10000: Antal: 4,41: SEK: FIRST NORTH SWEDEN - NORDIC@MID: Historik: Detaljer: 2021-03-04: Cyxone AB: Bert Roland Kari Junno: Styrelseordförande: Förvärv: Cyxone AB: SE0007815428: 2021-03-02 Market Cap: $2,064,327,953,861 24h Vol: $138,687,209,437 Dominance: BTC: 54.2% ETH: 12.0% Cryptocurrencies: 9,192 Markets: 37,971 ETH Gas: 79 Gwei Cyxone är ett biotekniskt företag vars specialistkompetens ligger inom utvecklandet av läkemedel med växtprotein som bas. Läkemedlet ämnar användas främst i behandling utav immunrelaterade sjukdomar och produkterna baseras på cyclotidteknologi. Avsikten är att läkemedlet skall kunna användas vid behandling utav multipel skleros.
Uroxatral dosage

4.85 5.19 Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price.

Latest Cyxone AB Share Price - Live CYX TO3 share price quotes, charts, profile, RNS & company financials for STO:CYX TO3 Stockopedia rates Cyxone AB as a Highly Speculative Sucker Stock 📉. 1 brokers rate it as a 'Buy'.
Iso 1400 version 2021 pdf

sa deuce
estetiskt program kursplan
kroppens anatomi indre organer
ikea italien
mitt tradera ändra uppgifter
a dub
fri fibernet

Nasdaq Stockholm meddelar Cyxone AB vite motsvarande två

Find the latest CYXONE AB SK-,75 (4CX.F) stock quote, history, news and other vital information to help you with your stock trading and investing. Latest Cyxone AB Share Price - Live CYX TO3 share price quotes, charts, profile, RNS & company financials for STO:CYX TO3 Stockopedia rates Cyxone AB as a Highly Speculative Sucker Stock 📉.